What Fueled The Previous Growth In The Convalescent Plasma Therapy Market?
The convalescent plasma therapy market has seen considerable growth due to a variety of factors.
• The market size for convalescent plasma therapy has seen a quick expansion in the last few years, elevating from $0.05 billion in 2024 and predicted to reach $0.06 billion in 2025, witnessing a compound annual growth rate (CAGR) of 11.4%.
Factors such as pandemics and widespread diseases, advancements in immunotherapy research, the authorization of emergency use, patient accessibility along with an increase in awareness among clinicians and public have significantly contributed to the history period growth.
How Does the Forecast Look for the Convalescent Plasma Therapy Market?
The convalescent plasma therapy market is expected to maintain its strong growth trajectory in upcoming years.
• It is projected that the convalescent plasma therapy market will experience fast-paced growth in the upcoming years, with an anticipated value of $0.09 billion by 2029, at a compound annual growth rate (CAGR) of 13.7%.
The predicted growth during this period is potentially due to emerging pathogens, development of immunotherapies, regulatory structures, global readiness, and public health projects. Significant trends expected during this forecasting period are standardization of collection and processing, focus on specific plasma components, tailor-made treatments, the usage of telemedicine and remote monitoring, and research into the long-term impacts.
What Are The Leading Drivers Of Growth In The Convalescent Plasma Therapy Market?
The growth of the convalescent plasma therapy market could be propelled by the superior efficiency and safety assessed during trials for COVID-19 Convalescent Plasma Therapy (CPT) within the forecast period. This form of transfusion has historically been used in treating various infectious disease outbreaks like SARS-1, Middle East Respiratory Syndrome (MERS), and the 2009 H1N1. A study undertaken by the Houston Methodist hospital in June 2022, aimed at assessing the safety and efficacy of COVID-19 convalescent plasma therapy, confirmed the procedure's safety and absence of adverse events, as well as its efficiency, with a recovery rate of 76%. In May 2020, another study in the Journal of Medical Virology reported potential reduced mortality rates in severely ill patients, observable positive effects on clinical symptoms, increased neutralizing antibody titers, and disappearance of SARS-CoV-2 RNA following convalescent plasma therapy. The therapy's safety and efficiency when handling COVID-19 cases will likely stimulate global growth in the convalescent plasma therapy market.
How Are The Segments Defined Within The Global Convalescent Plasma Therapy Market?
The convalescent plasma therapy market covered in this report is segmented –
1) By Antibody type: IgM, IgG, IgA
2) By Application: Prophylaxis, Treatment
3) By End-Users: Hospitals And Clinics, Laboratories And Research institutes
Subsegments:
1) By IgM: Early-Stage Infection Plasma, Acute Phase Plasma, Other IgM-Based Plasma Products
2) By IgG: High Titer IgG Plasma, Standard IgG Plasma, Other IgG-Based Plasma Products
3) By IgA: Plasma Rich In IgA, Specific IgA Antibody Plasma, Other IgA-Based Plasma Products
Pre-Book The Convalescent Plasma Therapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Convalescent Plasma Therapy Market?
The advancement of antibody-driven immunotherapy for potential use in treating COVID-19 presents significant potential for the convalescent plasma therapy market. Convalescent plasma therapy uses antibodies created in response to the coronavirus by a donor to enhance the immune response of the recipient. Companies are initiating trials, forming partnerships and investing in antibody-driven COVID-19 treatment. In August 2023, US-based biotech firm Regeneron Pharmaceuticals Inc. began a collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to support the clinical development, manufacturing, and licensing processes for a next-generation COVID-19 monoclonal antibody therapy aimed at preventing SARS-CoV-2 infection. This collaboration forms part of Project NextGen, a venture by the U.S. Department of Health and Human Services (HHS) to develop a stream of innovative COVID-19 vaccines and treatments. In line with the project's framework, Regeneron will independently design and propose an antibody candidate, which BARDA and Regeneron will evaluate and choose for further research, production, and regulatory efforts. The market growth is anticipated to be propelled by the focus on antibody-driven COVID-19 therapy, as convalescent plasma therapy employs antibodies.
Who Are the Key Players In The Convalescent Plasma Therapy Market?
Major companies operating in the convalescent plasma therapy market include:
• Bio Farma
• Hilton Pharma Ltd.
• Biotest AG
• BPL Ltd.
• LFB SA
• Octapharma AG
• CSL Behring LLC
• Takeda Pharmaceutical Company Ltd.
• Orthosera Kft.
• ADMA Biologics Inc.
• GC Biopharma Corp
• Grifols S.A
• Sanquin Plasma Products B.V.
• America's Blood Centers
• Blood Centers of America Inc.
• Anthem Inc.
• Laboratory Corporation of America Holdings
• Cerus Corporation
• Emergent BioSolutions Inc.
• Kedrion Biopharma Inc.
• New York Blood Center
• Blood Systems Inc.
• OneBlood Inc.
• Gulf Coast Regional Blood Center
• Bloodworks Northwest
• Blood Assurance Inc.
• New York Blood Center Inc.
• Honolulu Blood-Plasma Bank
• Community Blood Center
• LifeStream Blood Bank
What Is The Most Dominant Region In The Convalescent Plasma Therapy Market?
North America was the largest region in the convalescent plasma therapy market in 2023. Western Europe was the second largest region in the convalescent plasma therapy market. The regions covered in the convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
